{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:47:25Z","timestamp":1791510445894,"version":"4.3.4"},"reference-count":32,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,3,4]]},"published-print":{"date-parts":[[2025,5]]},"DOI":"10.2967\/jnumed.124.268959","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T07:16:29Z","timestamp":1742627789000},"page":"739-747","source":"Crossref","is-referenced-by-count":7,"title":["Dansylated Amino Acid\u2013Modified Long-Acting PSMA Derivatives<sup>68<\/sup>Ga\/<sup>177<\/sup>Lu-LNC1011 as Prostate Cancer Theranostics"],"prefix":"10.2967","volume":"66","author":[{"given":"Hongzhang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fantian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hehe","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"2025050105251684000_66.5.739.1","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res."},{"key":"2025050105251684000_66.5.739.2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S"},{"key":"2025050105251684000_66.5.739.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0820"},{"key":"2025050105251684000_66.5.739.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.186767"},{"key":"2025050105251684000_66.5.739.5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/ph14080713","article-title":"[68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer","volume":"14","author":"Hennrich","year":"2021","journal-title":"Pharmaceuticals (Basel)."},{"key":"2025050105251684000_66.5.739.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"2025050105251684000_66.5.739.7","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1007\/s00259-023-06229-w","article-title":"Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression","volume":"50","author":"Wen","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251684000_66.5.739.8","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1021\/acs.accounts.3c00309","article-title":"Exploiting albumin as a versatile carrier for cancer theranostics","volume":"56","author":"Tao","year":"2023","journal-title":"Acc Chem Res."},{"key":"2025050105251684000_66.5.739.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.107235"},{"key":"2025050105251684000_66.5.739.10","doi-asserted-by":"publisher","DOI":"10.7150\/thno.18719"},{"key":"2025050105251684000_66.5.739.11","doi-asserted-by":"publisher","DOI":"10.1039\/c5cs00158g"},{"key":"2025050105251684000_66.5.739.12","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00259-018-4004-5","article-title":"Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors","volume":"45","author":"Kelly","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251684000_66.5.739.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.221150"},{"key":"2025050105251684000_66.5.739.14","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1021\/acs.bioconjchem.8b00556","article-title":"Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors","volume":"29","author":"Wang","year":"2018","journal-title":"Bioconjugate Chem."},{"key":"2025050105251684000_66.5.739.15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","article-title":"First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Zang","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251684000_66.5.739.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242263"},{"key":"2025050105251684000_66.5.739.17","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00259-023-06470-3","article-title":"A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer","volume":"51","author":"Zang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251684000_66.5.739.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.250738"},{"key":"2025050105251684000_66.5.739.19","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","article-title":"Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol Pharmacetics."},{"key":"2025050105251684000_66.5.739.20","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1021\/acs.molpharmaceut.1c00994","article-title":"Preclinical investigations to explore the difference between the diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward prostate cancer therapy","volume":"19","author":"Borgna","year":"2022","journal-title":"Mol Pharmaceutics."},{"key":"2025050105251684000_66.5.739.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05837-2"},{"key":"2025050105251684000_66.5.739.22","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.7150\/thno.40482","article-title":"Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity","volume":"10","author":"Deberle","year":"2020","journal-title":"Theranostics."},{"key":"2025050105251684000_66.5.739.23","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.7150\/thno.96675","article-title":"Theranostics: a sure cure for cancer after 100 years?","volume":"14","author":"Song","year":"2024","journal-title":"Theranostics."},{"key":"2025050105251684000_66.5.739.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2010.10.004"},{"key":"2025050105251684000_66.5.739.25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.saa.2014.10.015","article-title":"Competitive binding of chlorin p6 and dansyl-l-proline to Sudlow\u2019s site II of human serum albumin","volume":"138","author":"Patel","year":"2015","journal-title":"Spectrochim Acta, Part A."},{"key":"2025050105251684000_66.5.739.26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jps.2600760510","article-title":"Fluorescence energy transfer study of the relationship between the lone tryptophan residue and drug binding sites in human serum albumin","volume":"76","author":"Kasai","year":"1987","journal-title":"J Pharm Sci."},{"key":"2025050105251684000_66.5.739.27","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.3390\/biomedicines10123020","article-title":"Pharmacological optimization of PSMA-based radioligand therapy","volume":"10","author":"Van der Gaag","year":"2022","journal-title":"Biomedicines."},{"key":"2025050105251684000_66.5.739.28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nucmedbio.2019.01.006","article-title":"Mini-review: targeted radiopharmaceuticals incorporating reversible, low molecular weight albumin binders","volume":"70","author":"Brandt","year":"2019","journal-title":"Nucl Med Biol."},{"key":"2025050105251684000_66.5.739.29","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","article-title":"Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC","volume":"48","author":"Kramer","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251684000_66.5.739.30","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00259-021-05539-1","article-title":"Head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-617 in dynamic PET\/CT evaluation of the same group of recurrent prostate cancer patients","volume":"49","author":"Wang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025050105251684000_66.5.739.31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13550-023-00981-8","article-title":"Multiparametric dynamic whole-body PSMA PET\/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007","volume":"13","author":"Dias","year":"2023","journal-title":"EJNMMI Res."},{"key":"2025050105251684000_66.5.739.32","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1007\/s00259-021-05420-1","article-title":"Pharmacokinetic studies of [68Ga]Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type","volume":"48","author":"Strauss","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T12:26:16Z","timestamp":1746102376000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.2967\/jnumed.124.268959"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268959","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}